炎性肝细胞腺瘤中ROS1、FRK和IL6的反复染色体重排激活JAK/STAT通路
该研究分析了504例患者发生的657个肝细胞腺瘤,发现45%为炎性肝细胞腺瘤(IHCA),其中81%存在IL6ST、FRK、STAT3、GNAS或JAK1突变。在未突变的IHCA中,RNA测序发现涉及ROS1、FRK或IL6的反复染色体重排,导致JAK/STAT通路激活。
要点
- 炎性肝细胞腺瘤中45%为IHCA,81%存在已知基因突变。
- 未突变IHCA中鉴定出ROS1、FRK或IL6的反复染色体重排。
- 这些重排导致JAK/STAT通路激活,解释了炎症表型。
核心结论
- 涉及ROS1、FRK或IL6基因的反复染色体改变导致IHCA中JAK/STAT通路激活。
研究设计与样本
- 分析了504例患者发生的657个肝细胞腺瘤,对17个基因进行表达分析,对7个基因进行测序。
- 对22个未突变的IHCA进行了全外显子组测序和/或RNA测序。
主要发现
- 鉴定出296个IHCA(45%),其中81%存在IL6ST(61%)、FRK(8%)、STAT3(5%)、GNAS(3%)或JAK1(2%)突变。
- 在未突变IHCA中,RNA测序发现涉及ROS1、FRK或IL6基因的反复染色体重排。
- 8个IHCA中鉴定出ROS1融合,涉及在肝脏高表达基因(PLG、RBP4、APOB)的C端部分与ROS1外显子33-35至43融合,包括酪氨酸激酶结构域;2例中鉴定出从外显子36至43的截短ROS1转录本。
- ROS1重排经FISH验证并导致ROS1过表达。
- 5个IHCA中鉴定出FRK重排,5种不同伙伴基因(MIA3、MIA2、LMO7、PLEKHA5、SEC16B)与FRK外显子3-8的common区域融合;未检测到FRK转录本过表达,但预测的嵌合蛋白缺乏自抑制SH2-SH3结构域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory hepatocellular adenomas (IHCAs) are benign liver tumours characterised by an activation of the janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway caused by oncogenic activating mutations. However, a subset of IHCA lacks of identified mutation explaining the inflammatory phenotype. METHODS: 657 hepatocellular adenomas developed in 504 patients were analysed for gene expression of 17 genes and for mutations in seven genes by sequencing. 22 non-mutated IHCAs were analysed by whole-exome and/or RNA sequencing. RESULTS: We identified 296 IHCA (45%), 81% of them were mutated in either IL6ST (61%), FRK (8%), STAT3 (5%), GNAS (3%) or JAK1 (2%). Among non-mutated IHCA, RNA sequencing identified recurrent chromosome rearrangement involving ROS1, FRK or IL6 genes. ROS1 fusions were identified in 8 IHCA, involving C-terminal part of genes highly expressed in the liver (PLG, RBP4, APOB) fused with exon 33-35 to 43 of ROS1 including the tyrosine kinase domain. In two cases a truncated ROS1 transcript from exon 36 to 43 was identified. ROS1 rearrangements were validated by fluorescence in situ hybridisation (FISH) and led to ROS1 overexpression. Among the 5 IHCA with FRK rearrangements, 5 different partners were identified (MIA3, MIA2, LMO7, PLEKHA5, SEC16B) fused to a common region in FRK that included exon 3-8. No overexpression of FRK transcript was detected but the predicted chimeric proteins lacked the auto-inhibitory SH2-SH3 domains. In two IHCA, we identified truncated 3'UTR of IL6 associated with overexpression of the transcript. CONCLUSION: Recurrent chromosomal alterations involving ROS1, FRK or IL6 genes lead to activation of the JAK/STAT pathway in IHCAs.
引用
- Bayard Q, Caruso S, Couchy G, et al. Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut. 2020. PMID: 31907296. doi:10.1136/gutjnl-2019-319790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。